Video Experimental Relacionado

Updated: May 24, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

El linfoma de Burkitt es el linfoma de Burkitt

Elizabeth M Molyneux¹, Rosemary Rochford, Beverly Griffin

¹College Of Medicine, Blantyre, Malawi. emolyneux@malawi.net

Lancet (London, England)

|February 16, 2012

Resumen

El linfoma de Burkitt, un cáncer de rápido crecimiento, está relacionado con el virus de Epstein-Barr y la activación del oncogén c-MYC. El éxito del tratamiento varía según la edad y la ubicación, con terapias futuras prometedoras como el rituximab.

Área de la Ciencia:

Oncología Oncología Oncología.
Hematología Hematología.
Virología Virología.

Sus antecedentes:

El linfoma de Burkitt es un linfoma no Hodgkin de células B agresivo, caracterizado por un rápido crecimiento tumoral.
Está asociado con el virus de Epstein-Barr y las translocaciones cromosómicas que activan el oncogén c-MYC.
Este linfoma es el cáncer infantil más común en las regiones endémicas de la malaria y prevalece en las personas infectadas por el VIH.

Objetivo del estudio:

Revisar las características, asociaciones y resultados del tratamiento del linfoma de Burkitt.
Para resaltar las disparidades en el tratamiento y los resultados basados en la edad del paciente y la ubicación geográfica.
Explorar posibles avances en la terapia, incluido el tratamiento con anticuerpos monoclonales.

Principales métodos:

Revisión de la literatura sobre la epidemiología, la patogénesis y el manejo clínico del linfoma de Burkitt.
Análisis de los resultados del tratamiento en diferentes poblaciones de pacientes (niños frente a adultos) y entornos de atención médica (países de bajos ingresos frente a países de altos ingresos).
Evaluación de estrategias terapéuticas emergentes, como el rituximab.

Principales resultados:

Los resultados para el linfoma de Burkitt son excelentes en niños con quimioterapia intensiva, pero pobres en adultos mayores.
La intensidad del tratamiento y las tasas de éxito difieren significativamente entre los países de bajos y altos ingresos.
El rituximab muestra potencial para mejorar los resultados y reducir la toxicidad.

Conclusiones:

El tratamiento del linfoma de Burkitt requiere quimioterapia intensiva y cuidados de apoyo robustos.
La edad y los factores socioeconómicos influyen críticamente en el éxito del tratamiento.
La terapia de anticuerpos monoclonales representa una dirección futura prometedora para mejorar el pronóstico del paciente.

Más Videos Relacionados

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

Videos de Conceptos Relacionados

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...